We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » XenoPort Reports Phase 2 Psoriasis Trial Met Primary Endpoints
XenoPort Reports Phase 2 Psoriasis Trial Met Primary Endpoints
XenoPort announced its Phase 2 clinical trial of an experimental drug for patients with moderate-to-severe chronic psoriasis met its primary endpoints.